ChartMill is a comprehensive online stock research platform designed to empower traders and investors with advanced tools for technical and fundamental analysis. The company provides a robust stock screener that allows users to filter thousands of stocks across major exchanges like NYSE, NASDAQ, and EURONEXT, using over 180 customizable technical and fundamental parameters to identify trading opportunities.
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
Looking for the S&P500 stocks that are experiencing notable gaps on Tuesday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session.
Global-e Online (GLBE) stock shows strong earnings momentum with 146% EPS growth and a bullish technical setup, signaling a potential breakout for growth investors.
Best Buy (BBY) offers a strong 4.83% dividend yield with a decade of growth. Its solid profitability and financial health support this sustainable income.
Palvella Therapeutics reported a wider Q3 2025 loss, missing EPS estimates. Investors focus on its strong cash position and upcoming clinical trial data for its rare disease pipeline.
Discover Innoviva (INVA), a potential value stock with strong fundamentals. Its attractive valuation, healthy balance sheet, and solid profitability suggest it trades below intrinsic worth.
Discover how Zymeworks (ZYME) combines strong technical trends with accelerating earnings and sales growth, making it a top high-growth stock candidate.
Discover high-growth stocks like COCO using the Minervini Trend Template. This method combines strong technical uptrends with accelerating earnings and sales momentum.
U.S. equities started the week with a clear breadth surge. Monday’s session (Nov 10) saw a convincing shift in participation, with improving leadership and technical strength across multiple timeframes. While not yet indicative of a full-blown uptrend, the breadth recovery strengthens the case for bullish continuation if follow-through persists.
Discover how Mueller Industries (MLI) exemplifies a powerful stock-picking strategy combining strong fundamentals, a bullish technical breakout, and attractive value.
National Fuel Gas Co (NFG) is a top growth stock at a reasonable price. It shows strong EPS and revenue growth, high profitability, and trades at an attractive valuation.
PTC stock fits Peter Lynch's GARP strategy with strong 25% earnings growth, a low PEG of 0.87, and robust profitability, trading at a reasonable price.
Zoom (ZM) offers a compelling value case with low P/E, strong profitability, and a debt-free balance sheet, aligning with classic value investing principles.
Autodesk (ADSK) offers strong growth, top-tier profitability, and a reasonable valuation for investors seeking affordable growth stocks in the software sector.
Solaris Energy Infrastructure (SEI) stock shows a powerful technical uptrend and explosive fundamental growth, meeting strict criteria for momentum investors.
The prospect of a quick end to the US government shutdown has rekindled investor confidence. Tech rebounds, semiconductors sprint ahead, and insurers feel political pressure building. Meanwhile, all eyes shift toward the last major earnings report of the season: Nvidia.
Lennox International excels with strong revenue & profit growth, a stellar 37.65% ROIC, and a healthy balance sheet, making it a top quality investment candidate.
ODDITY Tech offers strong growth at a fair price. With high revenue growth, profitability, and a reasonable P/E ratio, it fits the 'affordable growth' investment strategy.
Rigetti Q3 2025 results: Narrower-than-expected loss but revenue miss. Cash position strengthened to ~$600M. On track for 100+ qubit system by year-end.
Viant (DSP) Q3 2025 earnings beat EPS estimates by 62% with strong profit growth, despite a slight revenue miss. The company also provided optimistic Q4 guidance.
TransAct (TACT) Q3 2025 earnings: Revenue slightly missed estimates, but the company achieved a key milestone by returning to profitability, beating EPS forecasts.
ProKidney (PROK) reports Q3 2025 results, beating EPS estimates. Key updates include strong Phase 3 trial enrollment and a confirmed FDA accelerated approval pathway for its kidney disease therapy.
Arcturus Q3 2025 results show a revenue miss but a smaller-than-expected loss. The company advances its CF and OTC programs, with cash extending into 2028.
Zentalis (ZNTL) beat Q3 2025 earnings estimates. The biotech firm has no revenue but a strong cash position, with key data for its lead drug, azenosertib, expected in late 2026.
Gemini Space Station's Q3 2025 results show revenue beat estimates, but a larger-than-expected loss sent the stock tumbling over 12% in after-hours trading.
Green Dot (GDOT) reported mixed Q3 2025 results, beating earnings estimates but slightly missing on revenue. The company also raised its full-year 2025 profit guidance, signaling confidence.
Gevo Q3 2025 earnings show strong revenue beat and positive EBITDA, despite a wider net loss. The company advances its sustainable fuel projects and carbon credit sales.
REPAY Holdings (RPAY) reported Q3 2025 results, missing both revenue and EPS estimates. The stock fell as revenue of $77.7M and EPS of $0.21 fell short of expectations.
Ambac Financial (soon Octave) beat Q3 2025 revenue estimates and posted a narrower loss, signaling progress in its strategic shift to a specialty insurance firm.
Mereo BioPharma (MREO) beat Q3 EPS estimates with a narrower loss. The clinical-stage company has cash into 2027 and key data for its lead drug expected soon.
ON24 (ONTF) beat Q3 2025 earnings and revenue estimates. The digital engagement platform also raised its full-year outlook and showed strong cash flow growth.
Theravance Biopharma (TBPH) reported Q3 2025 results, beating EPS estimates with a profit of $0.04. Revenue was slightly below forecasts. Lead drug YUPELRI achieved record sales.
Insight Molecular Dx (IMDX) stock fell 11.8% after missing Q3 2025 revenue and EPS estimates. The company remains focused on its FDA submission for the GraftAssureDx™ test.
